All In Biotech

Drug Trial Radar · NCT01659255

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)

Last checked: Nov 20, 2026Latest source record: Mar 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Aug 17, 2012

Primary completion

Feb 23, 2015

Study completion Jan 11, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Aug 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Conditions

  • Non Hodgkins Lymphoma
  • Chronic Lymphocytic Leukaemia

Interventions

  • TirabrutinibDrug

    Capsules administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Dose-Limiting ToxicitiesTime frame: Day 1 through Day 28

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • CHRU - Hopital Claude HURIEZ

    Lille, France

  • Centre hospitalier Lyon Sud

    Lyon, France

  • CHU St Eloi

    Montpellier, France

  • University Hospital of Wales

    Cardiff, United Kingdom

  • Leicester Royal Infirmary

    Leicester, United Kingdom

  • Derriford Hospital

    Plymouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.